Status:
TERMINATED
Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Cardiac Amyloidosis
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
To estimate distribution's parameters of 18F-Flutemetamol (Vizamyl®) fixation on myocardium for patients with amyloid cardiac injuries.
Detailed Description
Hypothesis had been performed that PET with 18F-Flutemetamol (Vizamyl®) could lead an early diagnostic. Indeed, this tracer had been recently used to highlight inter-cerebral beta-amyloid plaques on p...
Eligibility Criteria
Inclusion
- Patients followed for amyloidosis with proved cardiac injury or strongly suspected:
- cardiac echography with typical signs of amyloid injury,
- anatomical result confirming presence of amyloid deposits at cardiac or peripheral level
- Signature of Informed Consent Form,
- Affiliation to a social security system
Exclusion
- Patient who suffers from another pathology which could lead cardiac injury (coronary disease, valvular disease, other pathology of deposit),
- Pregnancy and lactating women,
- Absence of effective contraception,
- Irradiating examination performed within the last 12 months or scheduled within the next 12 months,
- Unable patient physically, mentally or legally to provide informed consent,
- Patient under a system of legal protection
Key Trial Info
Start Date :
March 15 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 15 2019
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT03232632
Start Date
March 15 2017
End Date
September 15 2019
Last Update
August 26 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Toulouse
Toulouse, France, 31000